| Mifeprex (mifepristone) / Danco Laboratories |
ACTRN12624000103561: Mifepristone versus placebo to increase the rate of spontaneous labour in people with a prior caesarean: A double blind randomised controlled trial
(Mi-labourTrial)
|
|
|
| Not yet recruiting | 3 | 168 | | | University of Auckland, Auckland Medical Research Foundation | vaginal birth after caesarean, labour | | | | |
| Recruiting | 3 | 20 | | | Neurological Foundation, Neurological Foundation | Diagnostic and Statistical Manual 4th edition (DSM-IV) Major Depressive Episode in patients with Parkinson's Disease. | | | | |
| Recruiting | 3 | 40 | | | FPA Health, FPA Health Foundation | The effect of administering a progestogen receptor modulator with or without oestrogen on the ovarian function and quality of cervical mucus in women using the progestogen-only sub-dermal contraceptive, Implanon. | | | | |
ChiCTR-IIR-15007521: The efficacy and safety of using mifepristone in the treatment of uterine fibroids: a randomized, multiple-center controlled trial |
|
|
| Completed | 3 | 300 | | Three months of daily therapy with oral mifepristone (at a dose of 10 mg) ;Three months of daily therapy with oral mifepristone (at a dose of 25 mg) ;once-monthly subcutaneous injections of enantone (at a dose of 3.75 mg) | Peking University First Hospital; Peking University First Hospital, CR Zizhu Pharmaceutical Co., Ltd | Uterine fibroids | | | | |
ChiCTR-IIR-15007522: The efficacy and safety of using mifepristone in the treatment of uterine fibroids: a randomized, double-blind, placebo-controlled clinical trial |
|
|
| Completed | 3 | 132 | | started from 1-3 days of the menstrual cycle, one tablet of 10 mg mifepristone taken orally every day for 84 days ;started from 1-3 days of the menstrual cycle, one placebo tablet taken orally every day for 3 months | Peking University First Hospital; Peking University First Hospital, CR Zizhu Pharmaceutical Co., Ltd | Uterine fibroids | | | | |
| Ongoing | 3 | 670 | Europe | Medabon (mifepriston och misoprostol), G03XB01, Tablet, Sublingual tablet, Medabon (Mifepristone, Misoprostol), misoprostol | Concept Foundation, Concept Foundation | Termination of unwanted pregnancies of 64-140 days from last menses (verified by ultrasound), Termination of unwanted pregnancy, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2009-017222-39: Ensayo clínico aleatorizado, doble ciego, doble enmascarado, multicéntrico para evaluar la eficacia y seguridad de 5 mg de mifepristona oral comparado con triptorelina IM administrados durante 4 meses en el tratamiento de fibroma uterino |
|
|
| Ongoing | 3 | 74 | Europe | mifepristona, -, DECAPEPTYL MENSUAL 3,75 mg, polvo y disolvente para suspensión inyectable, DECAPEPTYL MENSUAL 3,75 mg, polvo y disolvente para suspensión inyectable | Laboratorios Litaphar S.A. | fibroma uterino | | | | |
2016-003753-14: CERVICAL PREPARATION UNDER PARACERVICAL BLOCK FOR THE ABORTION OF FIRST TRIMESTER: RANDOMIZED TRIAL PREPARATION CERVICALE DES IVG SOUS BLOC PARACERVICAL AU 1er TRIMESTRE: ESSAI CLINIQUE RANDOMISE |
|
|
| Not yet recruiting | 3 | 1 | Europe | MIFEGYNE, GYMISO200MICROG, MIFEPRISTONE, GYMISO 200MICROG, Cachet, MIFEPRISTONE 200 MG, GYMISO 200MICROG | Assistance Publique Hôpitaux de Marseille, AP-HM | The women are 18 years old or more, wishing an abortion under local anesthesia, between 6 and 14 weeks the day of the abortion. Patiente de 18 ans ou plus, désirant une interruption volontaire de grossesse (IVG) sous anesthésie locale (AL), entre 6semaines d'aménorhée (SA) et 14SA le jour de l'IVG, The women are 18 years old or more, wishing an abortion under local anesthesia, between 6 and 14 weeks the day of the abortion. Patiente de 18 ans ou plus, désirant une interruption volontaire de grossesse (IVG) sous anesthésie locale, entre 6SA et 14SA le jour de l'IVG, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2018-002367-26: Parallel group, blinded, multi-centre study of mifepristone in patients with endometriosis |
|
|
| Ongoing | 3 | 490 | Europe | Mifepristone 2.5 mg tablets, Mifepristone 5 mg tablets, Mifepristone 2.5 mg tablets, Mifepristone 5 mg tablets, Tablet | Litaphar Laboratorios, Litaphar Laboratorios | endometriosis in reproductive-age, endometriosis in reproductive-age, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2020-004302-63: A multi-centre, open-label, single-arm study assessing the safety and efficacy of 5 mg of mifepristone for the treatment of endometriosis in reproductive-age women during two treatment cycles of 24 weeks each |
|
|
| Ongoing | 3 | 300 | Europe | Mifepristone 5 mg, Mifepristone 5 mg, Tablet | Litaphar Laboratorios S.L., Litaphar Laboratorios S.L. | endometriosis in reproductive-age, endometriosis in reproductive-age, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
NCT05016349: Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. |
|
|
| Not yet recruiting | 3 | 160 | NA | All trans-retinoic acid, Vesanoid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone, Cannabidiol, Epidiolex, 9 cis retinoic acid, Tamoxifen, Standard therapy | Mahmoud Ramadan mohamed Elkazzaz, Ministry of Health, Saudi Arabia | Breast Cancer Female | 10/21 | 12/21 | | |
| Completed | 3 | 30 | US | Mifepristone, Misoprostol | Stanford University | Induced Vaginal Delivery | 04/23 | 04/23 | | |
NCT05304273: Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages |
|
|
| Recruiting | 3 | 120 | RoW | Mifepristone, Misoprostol 800 microgram vaginally, Letrozole | Calcutta National Medical College and Hospital | Miscarriage | 04/24 | 05/24 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
WOMEN, NCT06394999: Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive |
|
|
| Not yet recruiting | 3 | 1186 | Europe | Mifepristone 50 mg | Leiden University Medical Center, Karolinska Institutet, Women on Waves, Children's Investment Fund Foundation | Female Contraception | 09/28 | 09/29 | | |
| Recruiting | 3 | 400 | Europe | Mifepristone, Placebo | Chelsea and Westminster NHS Foundation Trust | Labor, Induced | 10/25 | 10/26 | | |
2006-002596-40: Comparison of two doses and two routes of administration of misoprostol after pre-treatment with mifepristone for early pregnancy termination: a randomized, placebo-controlled, multicentre trial |
|
|
| Ongoing | 2/3 | 188 | Europe | Cytotec, Mifegyne, Cytotec, Mifegyne, Cytotec | World Health Organization | Termination of early pregnancy | | | | |
